Results 251 to 260 of about 151,900 (300)
Some of the next articles are maybe not open access.
Nature Medicine
RAS family variants-most of which involve KRAS-are the most commonly occurring hotspot mutations in human cancers and are associated with a poor prognosis. For almost four decades, KRAS has been considered undruggable, in part due to its structure, which lacks small-molecule binding sites.
Anupriya Singhal +2 more
openaire +2 more sources
RAS family variants-most of which involve KRAS-are the most commonly occurring hotspot mutations in human cancers and are associated with a poor prognosis. For almost four decades, KRAS has been considered undruggable, in part due to its structure, which lacks small-molecule binding sites.
Anupriya Singhal +2 more
openaire +2 more sources
The Journal of Pathology, 2009
Abstract Somatic KRAS mutation is an early well‐known event in colorectal carcinogenesis but a complete understanding of RAS function and dysfunction in colorectal cancer is still to come.
Jehad, Abubaker +11 more
openaire +2 more sources
Abstract Somatic KRAS mutation is an early well‐known event in colorectal carcinogenesis but a complete understanding of RAS function and dysfunction in colorectal cancer is still to come.
Jehad, Abubaker +11 more
openaire +2 more sources
KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma
Molecular Cancer TherapeuticsAbstract Pancreatic ductal adenocarcinoma (PDAC) is associated with significant morbidity and mortality and is projected to be the second leading cause of cancer-related deaths by 2030.
Minh T. Than +3 more
openaire +2 more sources
Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches
Annals of Oncology, 2021Marina Garassino, D P Carbone, M Reck
exaly
Targeting the MAPK Pathway in KRAS-Driven Tumors
Cancer Cell, 2020Mariano Barbacid, Matthias Drosten
exaly
Targeting KRAS in pancreatic cancer: new drugs on the horizon
Cancer and Metastasis Reviews, 2021Misako Nagasaka +2 more
exaly